GC Cell Secures Patent for Novel Immune Cell Therapy, Offering Hope for Recurrent Cancers
Table of Contents
A breakthrough in immune cell therapy has emerged from GC Cell, with the company announcing the acquisition of a domestic patent for technology designed too significantly extend the lifespan and enhance the anti-cancer capabilities of immune cells. This innovation promises a new approach to treating recurrent cancer, perhaps overcoming limitations of existing therapies and bolstering the company’s position in the global biotechnology landscape.
Extending Immune Cell Lifespan for Enhanced Cancer Treatment
The newly patented technology centers around a unique method for treating CD5-positive tumors, a category of cancer cells. According to a company release, the approach focuses on maximizing anti-cancer effects by boosting immune cell activity and enabling them to survive and proliferate more effectively within the body. This offers potential new treatment avenues for cancers like lymphocytic leukemia.
The patent,officially registered on October 1,2025,covers a composition for both the prevention and treatment of cancer,utilizing an immune cell engineered to increase survival and proliferation rates while dramatically improving anti-tumor activity. This is achieved by simultaneously expressing OX40 ligand (OX40L) and IL-15 on a chimeric antigen receptor (CAR) targeting CD5.
GCC2005: A Differentiated CAR-NK Therapy in Clinical Trials
This core technology underpins GC Cell’s CAR-NK treatment candidate, GCC2005. The therapy is built on a platform designed for improved cell viability and proliferation and is currently undergoing phase 1 clinical trials in Korea. These trials are focused on patients with relapsed and refractory NK and T cell malignancies.
Current CAR-T cell therapies targeting similar conditions face challenges, including limited cell proliferation due to internal conflict, the risk of contamination with tumor cells, and potential damage to healthy T cells. However, GCC2005 distinguishes itself by utilizing NK cells sourced from healthy donors. This approach is anticipated to mitigate these risks and deliver superior tumor-killing capabilities.
Addressing Limitations of Existing Therapies
One analyst noted that the use of healthy donor NK cells represents a notable advantage, potentially circumventing the complexities and safety concerns associated with autologous CAR-T therapies. The ability to leverage the natural potency of NK cells, combined with the engineered CAR targeting CD5, could translate into a more effective and less toxic treatment option for patients.
“This patent registration is a meaningful achievement that officially recognizes GC Cell’s immune cell therapy technology,” stated Won Seong-yong, CEO of GC Cell. He further emphasized the company’s commitment to strengthening its global competitiveness through continued research and development of
News Report – Expanded and Edited
Why: GC cell has secured a patent for a novel immune cell therapy technology designed to improve the effectiveness of treatments for recurrent cancers,specifically CD5-positive tumors. The technology aims to overcome limitations of existing CAR-T cell therapies by utilizing NK cells from healthy donors.
Who: GC Cell, a biotechnology company, is the primary entity involved. Key individuals include Won Seong-yong, the CEO. Researchers and clinicians in Korea are conducting phase 1 clinical trials. Analysts are also observing the developments. Patients with relapsed and refractory NK and T cell malignancies are the target population.
What: GC Cell patented
Worth a look
